Shenfushu granules attenuate diabetic kidney disease by inhibiting PIK3R1/protein kinase B/heparanase-mediated endothelial-mesenchymal transition

Figure 4 Network pharmacology identifies potential targets of Shenfushu granules. A: Venn diagram of the methods used to identify potential targets of the active ingredients of Shenfushu granules in the treatment of diabetic kidney disease; B: Protein-protein interaction network diagram; C: Core targets; D: Gene Ontology enrichment analysis; E: Kyoto Encyclopedia of Genes and Genomes pathway analysis. SFSGs: Shenfushu granules; DKD: Diabetic kidney disease; MAPK: Mitogen-activated protein kinase; MAP: Mitogen-activated protein; ERK: Extracellular signal-regulated kinase; ATP: Adenosine triphosphate; BP: Biological process; CC: Cellular component; MF: Molecular function; EGFR: Epidermal growth factor receptor; PI3K: Phosphatidylinositol 3-kinase; AKT: Protein kinase B; TNF: Tumor necrosis factor; HIF-1: Hypoxia inducible factor-1.